Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

Company announcement - No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years, ...

GLP-1 medications have become game changers for people trying to lose weight, but bariatric surgery is still superior when it comes to total and lasting weight loss, a new study has found.Patients who ...

There was also an 8% lower risk of death from any cause among patients taking GLP-1 drugs like Novo Nordisk's Ozempic (semaglutide) and Eli Lilly's Trulicity (dulaglutide) for diabetes and Novo ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...